Core Viewpoint - Huaren Pharmaceutical (300110.SZ) announced a plan for Red Tower Innovation to reduce its holdings by up to 1% of the company's total share capital, equating to a maximum of 11.82 million shares, within three months starting from August 26, 2025, to November 25, 2025, through centralized bidding transactions [1] Summary by Category - **Company Announcement** - Huaren Pharmaceutical has disclosed a share reduction plan involving Red Tower Innovation, which will take place over a specified period [1] - **Share Reduction Details** - The reduction will not exceed 1% of the total share capital, amounting to a maximum of 11.82 million shares [1] - The timeframe for this reduction is set from August 26, 2025, to November 25, 2025 [1] - The method of reduction will be through centralized bidding transactions [1]

人民财讯8月3日电，华仁药业(300110)8月3日晚公告，红塔创新计划自减持计划公告之日起十五个交易 日后的三个月内（即2025年8月26日至2025年11月25日）通过集中竞价交易方式减持不超过公司总股本 1%的股份，即不超过1182万股。 （原标题：华仁药业：红塔创新计划减持不超过1%公司股份） ...

Core Viewpoint - Huaren Pharmaceutical (300110.SZ) has received approval for its medical foam dressing from the Shandong Provincial Drug Administration, marking a significant step in expanding its product offerings in the medical device sector [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., has been granted a Class II medical device registration certificate for the medical foam dressing [1] - The medical foam dressing is designed for covering non-chronic wounds on the body surface and is capable of absorbing wound exudate [1] - The product line includes 12 different models and specifications, catering to diverse clinical usage needs [1]

Core Viewpoint - Huaren Pharmaceutical (300110.SZ) has received approval for its medical foam dressing from the Shandong Provincial Drug Administration, indicating a significant advancement in its product offerings in the medical device sector [1] Group 1: Company Developments - The wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., has been granted a Class II medical device registration certificate for the medical foam dressing [1] - The medical foam dressing is designed for covering non-chronic wounds on the body surface and for absorbing wound exudate, showcasing the company's commitment to addressing diverse clinical needs [1] - The product line includes 12 different models and specifications, which allows for a wide range of clinical applications [1]

证券代码：300110 证券简称：华仁药业 公告编号：2025-046 华仁药业股份有限公司 关于全资子公司取得医疗器械注册证的公告 5、型号、规格：HRFL2-6/7、HRFL2-10/10、HRFL2-10/15、HRFL2-10/20、 HRFL2-10/25 、 HRFL2-10/30 、 HRFL2-14/20 、 HRFL2-14/30HRFL2-15/15 、 HRFL2-20/20、HRFL2-20/28、HRFL2-20/35 10、有效期至：2030 年 7 月 27 日 二、医疗器械相关情况 公司本次获得二类医疗器械注册证的医用泡沫敷料用于覆盖体表非慢性创面， 吸收创面渗出液，产品包含 12 个型号规格，能够满足多样化临床使用需求。目前 国内拥有医用泡沫敷料同类上市产品的企业共 90 家（数据来源：国家药品监督管 理局网站）。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司青岛华仁医疗用 品有限公司收到山东省药品监督管理局核准签发的"医用泡沫敷料"的《医疗器械注 册证》，现将相关情 ...

Group 1: Company Performance - Ningde Times reported a net profit of 30.5 billion yuan for the first half of the year, representing a year-on-year increase of 33.02% [1] - The company achieved revenue of 178.9 billion yuan, an increase of 7.27% compared to the same period last year [1] - Gross profit reached 44.8 billion yuan, up 14.45% year-on-year, with a gross margin of 25.02%, an increase of 1.57 percentage points from the previous year [1] Group 2: Stock Trading and Suspensions - Shangwei New Materials announced a suspension of trading due to multiple instances of abnormal stock price fluctuations, with the suspension expected to last no more than three trading days [2] - Jinchengzi is planning to acquire 55% of Samit Optoelectronics, leading to a stock suspension for up to ten trading days [3] - Sanchao New Materials is also planning a change in control, resulting in a stock suspension for up to two trading days [6] - Hehua Co. announced a stock suspension due to potential changes in its controlling shareholder [9] Group 3: Major Investments and Projects - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [5] - The company will use its own funds for this investment, with the final amount to be confirmed based on state-approved preliminary design estimates [5] Group 4: Other Corporate Actions - Sunshine Dairy's controlling shareholder sold a total of 1.1452 million shares, accounting for 0.41% of the company's total share capital, without triggering any significant changes in control [4] - Nanjing Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with uncertainty regarding whether it constitutes a major asset restructuring [7]

华仁药业7月30日公告，公司全资子公司青岛华仁医疗用品有限公司近日收到山东省药品监督管理局核 准签发的"一次性使用腹透置管手术包"的《医疗器械注册证》。该产品用于对肾功能衰竭患者进行腹膜 透析置管手术用，注册分类为Ⅱ类。目前国内拥有同类上市产品的企业共1家。此次取得注册证将进一 步丰富公司医疗器械产品线，提高产品综合竞争力，并助力公司原料药、制剂、医疗器械、医用包材等 板块的全面协同发展。但实际销售情况受市场实际需求及未来市场推广效果等因素影响，目前尚无法预 测其对公司未来业绩的影响。 ...

2024年1至12月份，华仁药业的营业收入构成为：医药工业占比93.83%，医药商业占比6.17%。 （文章来源：每日经济新闻） 华仁药业（SZ 300110，收盘价：3.69元）7月30日晚间发布公告称，近日，华仁药业股份有限公司全资 子公司青岛华仁医疗用品有限公司收到山东省药品监督管理局核准签发的"一次性使用腹透置管手术 包"的《医疗器械注册证》。产品名称为"一次性使用腹透置管手术包"。 ...

人民财讯7月30日电，华仁药业（300110）7月30日晚间公告，近日，公司全资子公司青岛华仁医疗用品 有限公司收到山东省药品监督管理局核准签发的"一次性使用腹透置管手术包"的《医疗器械注册证》。 ...

Core Viewpoint - Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., has received the "Medical Device Registration Certificate" for the "Disposable Peritoneal Dialysis Catheter Surgery Pack" from the Shandong Provincial Drug Administration [1] Group 1 - The company has successfully obtained regulatory approval for a new medical device product [1] - The product is specifically designed for peritoneal dialysis procedures, indicating a focus on renal care [1] - This approval may enhance the company's product portfolio and market presence in the medical supplies sector [1]